Attached files
file | filename |
---|---|
8-K - FORM 8-K - BioMed Realty Trust Inc | a59429e8vk.htm |
EX-99.2 - EX-99.2 - BioMed Realty Trust Inc | a59429exv99w2.htm |
Exhibit 99.1
CONTACT: | Rick Howe Director, Corporate Communications 858.207.5859 richard.howe@biomedrealty.com |
BIOMED REALTY TRUST REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS
Sustained, Strong Execution Results in 463,000 SF of Leasing and 7.7% Year-Over-Year Increase
in Same Property NOI on a Cash Basis
in Same Property NOI on a Cash Basis
SAN DIEGO, Calif. May 4, 2011 BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment
trust focused on Providing Real Estate to the Life Science Industry®, today announced financial
results for the first quarter ended March 31, 2011.
First Quarter 2011 Highlights
| Generated record total revenues for the second consecutive quarter of $105.5 million, up 13.8% from $92.8 million in the same period in 2010. Increased rental revenues for the quarter by 13.6% to $80.2 million from $70.6 million in the same period in 2010, also the highest in the companys history for the second consecutive quarter. |
| Increased same property net operating income on a cash basis for the quarter by 7.7% as compared to the same period in 2010. |
| Executed 27 leasing transactions representing approximately 463,000 square feet, the fourth consecutive quarter with an increase in total leasing volume: |
| Fifteen new leases totaling approximately 232,000 square feet. |
| Twelve leases amended to extend their terms, totaling approximately 231,000 square feet. |
| Increased the current consolidated operating portfolios weighted average leased percentage by 170 basis points to 90.3% leased, including positive net absorption in the Boston, San Francisco, San Diego, New York and Seattle markets. |
| Completed a public offering of $400 million of unsecured 3.85% Senior Notes due 2016. The company used the proceeds of the offering to repay a portion of the balance outstanding on its unsecured line of credit, which resulted in a loss on derivative instruments related to the ineffectiveness of cash flow hedges of approximately $1.0 million, or $0.01 per diluted share. |
| Increased funds from operations (FFO) for the quarter to $42.1 million ($0.29 per diluted share), as compared to $35.5 million ($0.32 per diluted share) in the first quarter of 2010, an increase of 18.6%. |
| Increased adjusted funds from operations (AFFO) for the quarter to $40.2 million ($0.28 per diluted share), as compared to $30.8 million ($0.27 per diluted share) in the first quarter of 2010, an increase of 30.7%. |
| Increased net income available to stockholders for the quarter to $5.5 million ($0.04 per diluted share), as compared to $4.3 million ($0.04 per diluted share) for the same period in 2010. |
| Increased dividend to $0.20 per share, or an annualized rate of $0.80 per share, a 17.6% increase over the prior quarter and a 42.9% increase over the prior year. |
Commenting on the first quarter results, Alan D. Gold, BioMeds Chairman and Chief Executive
Officer, said, Team BioMed kicked off 2011 with another record-breaking quarter of operating and
financial results, underscored by sustained leasing activity and robust same property NOI growth
which generated the highest quarterly total and rental revenues in the companys history. We are
especially pleased with our success in attracting and expanding relationships with premier life
science tenants throughout our portfolio. Notably, we signed new leases with Harvard University at
the Center for Life Science | Boston and Bionovo at our Bridgeview Technology Park in the San
Francisco Bay Area market, while expanding our relationships with Ironwood Pharmaceuticals in
Cambridge and NanoString Technologies in Seattle. Then, after quarter end, we were very pleased to
announce the completion of a 263,500 square foot lease with Logitech, a world leader in personal
peripherals, at the Pacific Research Center in the San Francisco Bay Area. These results provide
further evidence of the power of our business model built on a foundation of investing in
high-quality, well-located properties, as well as the steady execution of that model by our
best-in-class employees throughout the company.
First Quarter 2011 Financial Results
Total revenues for the first quarter were $105.5 million, compared to $92.8 million for the same
period in 2010, an increase of 13.8%, and the highest in the companys history for the second
consecutive quarter. Rental revenues for the first quarter were $80.2 million, compared to $70.6
million for the same period in 2010, an increase of 13.6%, also the highest in the companys
history for the second consecutive quarter.
The current operating portfolios weighted average leased percentage increased 170 basis points
from December 31, 2010 to 90.3% as of March 31, 2011. Same property net operating income on a cash
basis increased 7.7% for the quarter compared to the same period in 2010, primarily as a result of
the commencement of cash rents, driven by sustained leasing success, and contractual rent
escalations.
Net income available to common stockholders for the first quarter was $5.5 million, or $0.04 per
diluted share, compared to $4.3 million, or $0.04 per diluted share, for the same period in 2010.
FFO for the quarter was $42.1 million, or $0.29 per diluted share, compared to $35.5 million, or
$0.32 per diluted share, for the same period in 2010. As a result of the companys $400 million
unsecured debt offering, the company incurred a loss on derivative instruments related to the
ineffectiveness of cash flow hedges. Excluding the impact of the derivative loss, FFO would have
been $43.1 million, or $0.30 per diluted share. AFFO for the quarter was $40.2 million, or $0.28
per diluted share, compared to $30.8 million, or $0.27 per diluted share, for the same period in
2010.
2
FFO and AFFO are supplemental non-GAAP financial measures used in the real estate industry to
measure and compare the operating performance of real estate companies. A complete reconciliation
containing adjustments from GAAP net income available to common stockholders to FFO and AFFO and
definitions of terms are included at the end of this release.
Portfolio Update
During the quarter ended March 31, 2011, the company executed 27 leasing transactions representing
approximately 463,000 square feet, the fourth consecutive quarter with an increase in leasing
volume, comprised of:
| Fifteen new leases totaling approximately 232,000 square feet, including: |
| a new 51,500 square foot lease with Bionovo, Inc. at the companys Bridgeview Technology Park in Hayward, California; |
| a new 31,500 square foot lease with Harvard University at the Center for Life Science | Boston, bringing the property to 96% leased; |
| a 30,300 square foot lease expansion with Ironwood Pharmaceuticals, Inc. at 301 Binney Street in Cambridge, Massachusetts, which is owned through the companys joint venture with institutional investors advised by Prudential Real Estate Investors; |
| an 18,500 square foot lease expansion with NanoString Technologies, Inc. at the companys Fairview Research Center in Seattle, Washington; and |
| two new leases with Epizyme, Inc. and Sun Catalytix Corporation aggregating 28,000 square feet at the companys recently renovated Vassar Street property in Cambridge, Massachusetts. |
| Twelve leases amended to extend their terms, totaling approximately 231,000 square feet, including: |
| a 121,000 square foot lease extension with JFC International, Inc. at the companys Forbes Boulevard property in South San Francisco, California; and |
| a 28,100 square foot lease extension with Amira Pharmaceuticals, Inc. at the companys Waples Research Centre in San Diego, California. |
After the quarter end, the company announced the signing of a new, eleven-year lease with Logitech,
Inc. for approximately 263,500 square feet of office space at the Pacific Research Center in
Newark, California, increasing occupancy at the campus to 43%.
At March 31, 2011, the companys total portfolio comprised 85 properties and 12.2 million square
feet, with an additional 2.6 million square feet of development potential. The current operating
portfolio weighted average lease percentage was approximately 90.3% leased at quarter end.
3
The companys property portfolio included the following as of March 31, 2011:
Rentable Square Feet | ||||
Current operating |
10,498,060 | |||
Long-term lease up |
1,389,517 | |||
Development |
176,000 | |||
Pre-development |
152,145 | |||
Total property portfolio |
12,215,722 | |||
Development potential |
2,626,000 | |||
Total portfolio |
14,841,722 | |||
Financing Activity
During the first quarter, the company completed the following debt-related transactions:
| Completed public offering of $400 million of unsecured 3.85% Senior Notes due 2016. |
| Completed the exchange offer of $250 million of unregistered 6.125% Senior Notes due 2020 for an equal principal amount of a new issue of registered 6.125% Senior Notes due 2020. |
| Voluntarily prepaid $25.5 million of previously outstanding mortgages. |
As a result of these transactions, at March 31, 2011:
| Debt to total assets ratio was reduced to 38.5% as compared to 42.4% a year ago. |
| Secured debt to total assets ratio was reduced to 15.9% as compared to 24.3% a year ago, and unencumbered rents as a percentage of total rents increased to 69.4% as compared to 63.8% a year ago. |
| Weighted average debt maturity was extended to 6.9 years as compared to 5.8 years a year ago. |
| Floating rate debt exposure was reduced to 3.3% from 38.2% a year ago. |
| Line capacity totaled $661.2 million. |
We continued along our path of steady, proactive management of our balance sheet during the first
quarter, highlighted by completing an unsecured bond issuance of $400 million, our second unsecured
financing since achieving investment grade corporate credit ratings in 2010, said Greg Lubushkin,
Chief Financial Officer of BioMed. Access to this efficiently priced capital has proven to be a
valuable means of enhancing our long-standing ability to properly manage our capital structure and
execute our business plan. In combination with our sustained operating success, our prudent
stewardship of the companys capital enabled us to raise our first quarter common stock dividend to
$0.20 per share, an 18% increase from the fourth quarter of last year and 43% above the first
quarter 2010 dividend. We are focused on
continuing to leverage the financial flexibility achieved as a result of the disciplined execution
of our capital structure to fuel BioMeds growth and create value for our stockholders.
4
Quarterly and Annual Distributions
BioMed Realty Trusts board of directors previously declared a first quarter 2011 dividend of $0.20
per share of common stock, and a dividend of $0.46094 per share of the companys 7.375% Series A
Cumulative Redeemable Preferred Stock for the period from January 16, 2011 through April 15, 2011.
The first quarter common share dividend represented a 17.6% increase over the fourth quarter 2010
dividend, and is equivalent to an annualized dividend of $0.80 per common share.
Earnings Guidance
The company has revised its 2011 guidance for net income per diluted share and FFO per diluted
share to reflect approximately $0.04 of dilution from the companys unsecured debt offering
completed in March 2011 and actual first quarter operating results and leasing success. The
companys revised guidance is set forth and reconciled below.
2011 | ||||
(Low - High) | ||||
Projected net income per diluted share available
to common stockholders |
$ | 0.13 - $0.19 | ||
Add: |
||||
Noncontrolling interests in operating partnership |
$ | 0.00 | ||
Real estate depreciation and amortization |
$ | 1.02 | ||
Projected FFO per diluted share |
$ | 1.15 - $1.21 |
The foregoing estimates are forward-looking and reflect managements view of current and future
market conditions, including certain assumptions with respect to leasing activity, rental rates,
occupancy levels, interest rates, and the amount and timing of development and redevelopment
activities. The companys actual results may differ materially from these estimates.
Supplemental Information
Supplemental operating and financial data are available in the Investor Relations section of the
companys website at www.biomedrealty.com.
Teleconference and Webcast
BioMed will conduct a conference call and webcast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern
Time) on Thursday, May 5, 2011 to discuss the companys financial results and operations for the
quarter. The call will be open to all interested investors either through a live audio web cast at
the Investor Relations
5
section of the companys web site at www.biomedrealty.com and at
www.earnings.com, which will include an online slide presentation to accompany the call, or live by
calling 866-713-8395 (domestic) or 617-597-5309 (international) with call ID number 28805057. The
complete webcast will be archived for 30 days on both web sites. A telephone playback of the
conference call will also be available from 1:00 p.m. Pacific Time on Thursday, May 5, 2011 until
midnight Pacific Time on Tuesday, May 10, 2011 by calling 888-286-8010 (domestic) or 617-801-6888
(international) and using access code 54845839.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate
to the Life Science Industry®. The companys tenants primarily include biotechnology and
pharmaceutical companies, scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed owns or has interests in 85 properties, representing
147 buildings with approximately 12.2 million rentable square feet. The companys properties are
located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco,
Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as
centers for scientific research. Additional information is available
at www.biomedrealty.com.
This press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions
that involve risks and uncertainties that could cause actual outcomes and results to differ
materially. These risks and uncertainties include, without limitation: general risks affecting the
real estate industry (including, without limitation, the inability to enter into or renew leases,
dependence on tenants financial condition, and competition from other developers, owners and
operators of real estate); adverse economic or real estate developments in the life science
industry or the companys target markets; risks associated with the availability and terms of
financing, the use of debt to fund acquisitions and developments, and the ability to refinance
indebtedness as it comes due; failure to maintain the companys investment grade credit ratings
with the ratings agencies; failure to manage effectively the companys growth and expansion into
new markets, or to complete or integrate acquisitions and developments successfully; reductions in
asset valuations and related impairment charges; risks and uncertainties affecting property
development and construction; risks associated with downturns in the national and local economies,
increases in interest rates, and volatility in the securities markets; potential liability for
uninsured losses and environmental contamination; risks associated with the companys potential
failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible
adverse changes in tax and environmental laws; and risks associated with the companys dependence
on key personnel whose continued service is not guaranteed. For a further list and description of
such risks and uncertainties, see the reports filed by the company with the Securities and Exchange
Commission, including the companys most recent annual report on Form 10-K and quarterly reports on
Form 10-Q. The company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.
# # #
(Financial Tables Follow)
6
BIOMED REALTY TRUST, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(In thousands, except share data)
March 31, | December 31, | |||||||
2011 | 2010 | |||||||
(Unaudited) | ||||||||
ASSETS |
||||||||
Investments in real estate, net |
$ | 3,538,560 | $ | 3,536,114 | ||||
Investments in unconsolidated partnerships |
56,287 | 57,265 | ||||||
Cash and cash equivalents |
19,351 | 21,467 | ||||||
Restricted cash |
6,687 | 9,971 | ||||||
Accounts receivable, net |
7,358 | 5,874 | ||||||
Accrued straight-line rents, net |
110,981 | 106,905 | ||||||
Acquired above-market leases, net |
28,069 | 30,566 | ||||||
Deferred leasing costs, net |
121,658 | 125,060 | ||||||
Deferred loan costs, net |
13,473 | 11,499 | ||||||
Other assets |
56,656 | 55,033 | ||||||
Total assets |
$ | 3,959,080 | $ | 3,959,754 | ||||
LIABILITIES AND EQUITY |
||||||||
Mortgage notes payable, net |
$ | 629,640 | $ | 657,922 | ||||
Exchangeable senior notes, net |
199,613 | 199,522 | ||||||
Unsecured senior notes, net |
645,081 | 247,571 | ||||||
Unsecured line of credit |
51,000 | 392,450 | ||||||
Security deposits |
11,585 | 11,749 | ||||||
Dividends and distributions payable |
31,086 | 27,029 | ||||||
Accounts payable, accrued expenses and other liabilities |
88,116 | 98,826 | ||||||
Derivative instruments |
2,231 | 3,826 | ||||||
Acquired below-market leases, net |
7,565 | 7,963 | ||||||
Total liabilities |
1,665,917 | 1,646,858 | ||||||
Equity: |
||||||||
Stockholders equity: |
||||||||
Preferred stock, $.01 par value, 15,000,000 shares
authorized: 7.375% Series A cumulative redeemable
preferred stock, $230,000,000 liquidation preference
($25.00 per share), 9,200,000 shares issued and
outstanding at March 31, 2011 and December 31, 2010 |
222,413 | 222,413 | ||||||
Common stock, $.01 par value, 200,000,000 shares
authorized, 131,239,482 and 131,046,509 shares issued
and outstanding at March 31, 2011 and December 31,
2010, respectively |
1,312 | 1,310 | ||||||
Additional paid-in capital |
2,369,922 | 2,371,488 | ||||||
Accumulated other comprehensive loss |
(68,908 | ) | (70,857 | ) | ||||
Dividends in excess of earnings |
(241,894 | ) | (221,176 | ) | ||||
Total stockholders equity |
2,282,845 | 2,303,178 | ||||||
Noncontrolling interests |
10,318 | 9,718 | ||||||
Total equity |
2,293,163 | 2,312,896 | ||||||
Total liabilities and equity |
$ | 3,959,080 | $ | 3,959,754 | ||||
7
BIOMED REALTY TRUST, INC.
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except share data)
(Unaudited)
(In thousands, except share data)
(Unaudited)
For the Three Months Ended | ||||||||
March 31, | ||||||||
2011 | 2010 | |||||||
Revenues: |
||||||||
Rental |
$ | 80,217 | $ | 70,600 | ||||
Tenant recoveries |
24,581 | 20,826 | ||||||
Other income |
747 | 1,330 | ||||||
Total revenues |
105,545 | 92,756 | ||||||
Expenses: |
||||||||
Rental operations |
20,517 | 17,851 | ||||||
Real estate taxes |
10,681 | 8,722 | ||||||
Depreciation and amortization |
33,835 | 28,915 | ||||||
General and administrative |
7,421 | 6,269 | ||||||
Acquisition related expenses |
320 | 150 | ||||||
Total expenses |
72,774 | 61,907 | ||||||
Income from operations |
32,771 | 30,849 | ||||||
Equity in net loss of unconsolidated partnerships |
(648 | ) | (277 | ) | ||||
Interest income |
125 | 20 | ||||||
Interest expense |
(21,316 | ) | (21,260 | ) | ||||
(Loss)/gain on derivative instruments |
(1,011 | ) | 150 | |||||
Loss on extinguishment of debt |
(43 | ) | (821 | ) | ||||
Net income |
9,878 | 8,661 | ||||||
Net income attributable to noncontrolling interests |
(107 | ) | (121 | ) | ||||
Net income attributable to the Company |
9,771 | 8,540 | ||||||
Preferred stock dividends |
(4,241 | ) | (4,241 | ) | ||||
Net income available to common stockholders |
$ | 5,530 | $ | 4,299 | ||||
Net income per share available to common stockholders: |
||||||||
Basic and diluted earnings per share |
$ | 0.04 | $ | 0.04 | ||||
Weighted-average common shares outstanding: |
||||||||
Basic |
129,771,733 | 98,229,996 | ||||||
Diluted |
132,764,842 | 102,577,329 | ||||||
8
BIOMED REALTY TRUST, INC.
CONSOLIDATED FUNDS FROM OPERATIONS
(In thousands, except share data)
(Unaudited)
(In thousands, except share data)
(Unaudited)
Our FFO available to common shares and partnership and LTIP units and a reconciliation to net
income for the three months ended March 31, 2011 and 2010 was as follows:
Three Months Ended | ||||||||
March 31, | ||||||||
2011 | 2010 | |||||||
Net income available to the common stockholders |
$ | 5,530 | $ | 4,299 | ||||
Adjustments: |
||||||||
Noncontrolling interests in operating partnership |
125 | 127 | ||||||
Interest expense on Notes due 2030 |
1,688 | 1,506 | ||||||
Depreciation and amortization unconsolidated partnerships |
921 | 662 | ||||||
Depreciation and amortization consolidated entities |
33,835 | 28,915 | ||||||
Depreciation and amortization allocable to noncontrolling
interest of consolidated joint ventures |
(26 | ) | (22 | ) | ||||
Funds from operations available to common shares and units diluted |
$ | 42,073 | $ | 35,487 | ||||
Funds from operations per share diluted |
$ | 0.29 | $ | 0.32 | ||||
Weighted-average common shares and units outstanding diluted (1) |
144,167,342 | 112,491,405 | ||||||
Our AFFO available to common shares and partnership and LTIP units and a reconciliation
of FFO to AFFO for the three months ended March 31, 2011 and 2010 was as follows:
Three Months Ended | ||||||||
March 31, | ||||||||
2011 | 2010 | |||||||
Funds from operations available to common shares and
Units diluted |
$ | 42,073 | $ | 35,487 | ||||
Adjustments: |
||||||||
Recurring capital expenditures and tenant improvements |
(2,045 | ) | (2,834 | ) | ||||
Leasing commissions |
(3,629 | ) | (424 | ) | ||||
Non-cash revenue adjustments |
(1,541 | ) | (7,127 | ) | ||||
Non-cash debt adjustments |
3,080 | 3,310 | ||||||
Non-cash equity compensation |
1,871 | 1,789 | ||||||
Depreciation included in general and administrative
expenses |
386 | 347 | ||||||
Share of non-cash unconsolidated partnership adjustments |
42 | 243 | ||||||
Adjusted funds from operations available to common shares and
units |
$ | 40,237 | $ | 30,791 | ||||
Adjusted funds from operations per share diluted |
$ | 0.28 | $ | 0.27 | ||||
Weighted-average common shares and units outstanding
diluted (1) |
144,167,342 | 112,491,405 | ||||||
9
(1) | The three months ended March 31, 2011 and March 31, 2010 each include 9,914,076 shares of common stock potentially issuable pursuant to the exchange feature of the exchangeable senior notes due 2030 based on the if converted method. The three months ended March 31, 2011 includes 1,488,424 shares of unvested restricted stock, which are considered anti-dilutive for purposes of calculating diluted earnings per share. |
We present funds from operations, or FFO, and adjusted funds from operations, or AFFO,
available to common shares and partnership and LTIP units because we consider them important
supplemental measures of our operating performance and believe they are frequently used by
securities analysts, investors and other interested parties in the evaluation of REITs, many of
which present FFO and AFFO when reporting their results.
FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate
and related assets, which assumes that the value of real estate assets diminishes ratably over
time. Historically, however, real estate values have risen or fallen with market conditions.
Because FFO excludes depreciation and amortization unique to real estate, gains and losses from
property dispositions and extraordinary items, it provides a performance measure that, when
compared year over year, reflects the impact to operations from trends in occupancy rates, rental
rates, operating costs, development activities and interest costs, providing perspective not
immediately apparent from net income. We compute FFO in accordance with standards established by
the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in
its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO
represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of
property, plus real estate related depreciation and amortization (excluding amortization of loan
origination costs) and after adjustments for unconsolidated partnerships and joint ventures.
We calculate AFFO by adding to FFO: (a) amounts received pursuant to master lease agreements
on certain properties, which are not included in rental income for GAAP purposes, (b) non-cash
revenues and expenses, (c) recurring capital expenditures and tenant improvements, and (d) leasing
commissions.
Our computation of FFO and AFFO may differ from the methodology for calculating FFO and AFFO
utilized by other equity REITs and, accordingly, may not be comparable to such other REITs.
Further, FFO and AFFO do not represent cash flow available for managements discretionary use
because of needed capital replacement or expansion, debt service obligations, or other commitments
and uncertainties. FFO and AFFO should not be considered as an alternative to net income (loss)
(computed in accordance with GAAP) as an indicator of our financial performance or to cash flow
from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor
is it indicative of funds available to fund our cash needs, including our ability to pay dividends
or make distributions. FFO and AFFO should be considered only as supplements to net income computed
in accordance with GAAP as measures of our operations.
10